Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Morales

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Cancer Research|July 3, 2008
Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinomaJoan Montero, Albert Morales, Laura Llacuna, et al.
Hepatology (Baltimore, Md.)|August 24, 2010
Growth arrest-specific protein 6 is hepatoprotective against murine ischemia/reperfusion injuryLaura Llacuna, Cristina Bárcena, Lola Bellido-Martín, et al.
Cancers|February 7, 2020
Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma ModelsBlanca Cucarull, Anna Tutusaus, Miguel Subías, et al.
Scientific Reports|January 22, 2015
Angiogenin secretion from hepatoma cells activates hepatic stellate cells to amplify a self-sustained cycle promoting liver cancerCristina Bárcena, Milica Stefanovic, Anna Tutusaus, et al.
Frontiers in Immunology|May 31, 2024
Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASHSturla Magnus Grøndal, Anna Tutusaus, Loreto Boix, et al.
Oncotarget|April 24, 2018
Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinomaAnna Tutusaus, Milica Stefanovic, Loreto Boix, et al.
Cellular and Molecular Gastroenterology and Hepatology|November 6, 2019
A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic TargetAnna Tutusaus, Estefanía de Gregorio, Blanca Cucarull, et al.
Frontiers in Immunology|June 23, 2025
Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stagesCarla Fuster-Anglada, Josep Corominas, Aida Marsal, et al.
Journal of Personalized Medicine|March 29, 2023
Prognostic Value of Soluble AXL in Serum from Heart Failure Patients with Preserved and Reduced Left Ventricular Ejection FractionHelena Cristóbal, Cristina Enjuanes, Montserrat Batlle, et al.
Journal of Hepatology|April 25, 2015
Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivationCristina Bárcena, Milica Stefanovic, Anna Tutusaus, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Cancer Research|July 3, 2008
Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinomaJoan Montero, Albert Morales, Laura Llacuna, et al.
Hepatology (Baltimore, Md.)|August 24, 2010
Growth arrest-specific protein 6 is hepatoprotective against murine ischemia/reperfusion injuryLaura Llacuna, Cristina Bárcena, Lola Bellido-Martín, et al.
Cancers|February 7, 2020
Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma ModelsBlanca Cucarull, Anna Tutusaus, Miguel Subías, et al.
Scientific Reports|January 22, 2015
Angiogenin secretion from hepatoma cells activates hepatic stellate cells to amplify a self-sustained cycle promoting liver cancerCristina Bárcena, Milica Stefanovic, Anna Tutusaus, et al.
Frontiers in Immunology|May 31, 2024
Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASHSturla Magnus Grøndal, Anna Tutusaus, Loreto Boix, et al.
Oncotarget|April 24, 2018
Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinomaAnna Tutusaus, Milica Stefanovic, Loreto Boix, et al.
Cellular and Molecular Gastroenterology and Hepatology|November 6, 2019
A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic TargetAnna Tutusaus, Estefanía de Gregorio, Blanca Cucarull, et al.
Frontiers in Immunology|June 23, 2025
Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stagesCarla Fuster-Anglada, Josep Corominas, Aida Marsal, et al.
Journal of Personalized Medicine|March 29, 2023
Prognostic Value of Soluble AXL in Serum from Heart Failure Patients with Preserved and Reduced Left Ventricular Ejection FractionHelena Cristóbal, Cristina Enjuanes, Montserrat Batlle, et al.
Journal of Hepatology|April 25, 2015
Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivationCristina Bárcena, Milica Stefanovic, Anna Tutusaus, et al.
Pageof 8